Squibb K S, Ridlington J W, Carmichael N G, Fowler B A
Environ Health Perspect. 1979 Feb;28:287-96. doi: 10.1289/ehp.7928287.
Circulating cadmium-thionein (Cd-MT) is cleared from the mammalian circulatory system by filtration through the kidney glomerulus with subsequent reabsorption by kidney proximal tubules. Damage to the tubules results following uptake of Cd-MT, which is dependent upon time and the dose level of cadmium administered. Intravenous administration of 109Cd-MT at doses of 0.017 and 0.17 mg Cd/kg body weight with examination of total renal uptake of 109Cd at 0.5, 3, and 24 hr disclosed that the rate of clearance from the blood and uptake by the kidney was significantly more rapid at the 0.017 mg Cd/kg dose. Ultrastructural changes resulting from intravenous injection of either form A or B of Cd-MT were characterized by increased numbers of pinocytotic vesicles and small, dense lysosomal structures. There was no evidence of mitochondrial swelling or cell death at either 3 or 6 hr after injection. The subcellular distribution of cadmium in kidney tissue at various times after administration of Cd-MT was determined by using differential centrifugation techniques with 109Cd and in situ by using x-ray microanalysis. At 30 min after injection of Cd-MT, significant amounts of cadmium were present in lysosomal fractions indicating an interaction between the tubular lysosome system and Cd-MT prior to the onset of overt cellular toxicity. Results suggest that Cd-MT is reabsorbed and broken down by kidney tubule cells in a physiological manner with possible subsequent release of the toxic cadmium ion.
循环中的镉硫蛋白(Cd-MT)通过肾小球滤过从哺乳动物循环系统中清除,随后被近端肾小管重吸收。Cd-MT被摄取后会导致肾小管损伤,这取决于镉的给药时间和剂量水平。静脉注射剂量为0.017和0.17mg镉/千克体重的109Cd-MT,并在0.5、3和24小时检查109Cd的总肾摄取量,结果显示,剂量为0.017mg镉/千克体重时,血液清除率和肾脏摄取率明显更快。静脉注射A型或B型Cd-MT导致的超微结构变化的特征是胞饮小泡数量增加以及小而致密的溶酶体结构。注射后3或6小时均未发现线粒体肿胀或细胞死亡的迹象。通过使用109Cd的差速离心技术以及通过X射线微分析原位测定给药后不同时间肾脏组织中镉的亚细胞分布。注射Cd-MT后30分钟,溶酶体组分中存在大量镉,这表明在明显的细胞毒性出现之前,肾小管溶酶体系统与Cd-MT之间存在相互作用。结果表明,Cd-MT被肾小管细胞以生理方式重吸收并分解,随后可能释放出有毒的镉离子。